Dermatology

Latest News

OX40 Antagonist Amlitelimab Meets Primary and Secondary Endpoints in Late-Stage COAST-1 Trial / image credit Sanofi logo ©Florence Plot/stock.adobe.com
OX40 Antagonist Amlitelimab Meets All Primary and Secondary Endpoints in Phase 3 Atopic Dermatitis Trial

September 11th 2025

Sanofi's amlitelimab, dosed every 4 or 12 weeks, was superior to placebo in efficacy and skin clearance, with efficacy increasing throughout the treatment period.

Evommune Launches Phase 2b Trial of Oral MRGPRX2 Antagonist, EVO756, In Adults With Atopic Dermatitis / image credit atopic dermatitis ©designua/stock.adobe.com
Evommune Launches Phase 2b Trial of Oral MRGPRX2 Antagonist, EVO756, In Adults With Atopic Dermatitis

August 27th 2025

AAD Atopic Dermatitis Treatment Update: A Q&A With Linda Stein Gold, MD
AAD Atopic Dermatitis Treatment Update: A Q&A With Linda Stein Gold, MD

August 27th 2025

Investigational Oral IL-23 Receptor Antagonist Improves Skin Clearance in Psoriasis: Daily Dose / image credit: ©New Africa/AdobeStock
Investigational Oral IL-23 Receptor Antagonist Improves Skin Clearance in Psoriasis: Daily Dose

August 25th 2025

Upadacitinib Shows Significant Hair Regrowth in Second Phase 3 Trial for Severe Alopecia Areata
Upadacitinib Shows Significant Hair Regrowth in Second Phase 3 Trial for Severe Alopecia Areata

August 22nd 2025

Latest CME Events & Activities

More News


Site Logo

Role of Anti–SS-A and Anti–SS-B Tests in Sjögren Diagnosis

December 31st 2006

I enjoyed the article by Kenneth H. Fye, MD, "Rheumatic Disease: How to Use theLab in the Workup" (CONSULTANT, March 2004, page 369). However, I foundthe following statement to be misleading: "Anti-SS-A and anti-SS-B determinationsare necessary to rule out Sjgren syndrome in patients with sicca complaints."If the results of these tests are negative, but Sjgren syndrome was initiallysuspected based on the history, labial biopsy is required. Many persons with thisdisease have negative antibody test results.Unfortunately, it often takes years before Sjgren syndrome is correctly diagnosedin most patients. This is usually because a health care provider rules it outbased on negative results of anti-SS-A and anti-SS-B tests.---- Paula Hochberg, ARNPSarasota, FlaYou are correct that negative results of tests foranti-SS-A and anti-SS-B antibodies do not ruleout Sjgren syndrome. Although the majorityof patients with this syndrome have these antibodies,a significant minority do not. If, in thislatter group of patients, Sjgren syndrome is strongly suspectedon clinical grounds, a minor salivary gland biopsyshould be considered. Biopsy is the most specific andsensitive test for Sjgren syndrome. Although a biopsy isnot required to make the diagnosis in every patient, thereare clearly those with negative tests for anti-SS-A andanti-SS-B in whom a biopsy is necessary to confirm suspectedSjgren syndrome. Thus, my statement shouldhave read instead, "Positive anti-SS-A and anti-SS-B determinationssupport a diagnosis of Sjgren syndrome inpatients with sicca complaints."---- Kenneth H. Fye, MDClinical Professor of MedicineRheumatology DivisionUniversity of California, San Francisco,School of Medicine

© 2025 MJH Life Sciences

All rights reserved.